Averitas Drug Patent Portfolio

Averitas owns 2 orange book drugs protected by 14 US patents Given below is the list of Averitas's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9012469 Crystalline naloxol-peg conjugate 02 Apr, 2032
Active
US8821920 Therapeutic patch for transdermal delivery of capsaicin 26 Mar, 2030
Active
US9226903 Transdermal therapeutic system comprising an adhesive layer method for siliconizing the back layer or the system and use of said back layer 15 Dec, 2028
Active
US7786133 Chemically modified small molecules 16 Sep, 2028
Active
US10034841 Transdermal therapeutic system comprising an adhesive layer method for siliconizing the back layer of the system and use of said back layer 06 Sep, 2025 Expired
US8067431 Chemically modified small molecules 16 Dec, 2024 Expired
US7056500 Polymer conjugates of opioid antagonists 29 Jun, 2024 Expired
US10463598 Compositions and kits for the removal of irritating compounds from bodily surfaces 05 Sep, 2023 Expired
US10869827 Compositions and kits for the removal of irritating compounds from bodily surfaces 05 Sep, 2023 Expired
US8263059 Compositions and kits for the removal of irritating compounds from bodily surfaces 05 Sep, 2023 Expired
US8889113 Compositions and kits for the removal of irritating compounds from bodily surfaces 05 Sep, 2023 Expired
US7662365 Polymer conjugates of opioid antagonists 18 Oct, 2022 Expired
US8617530 Polymer conjugates of opioid antagonists 18 Oct, 2022 Expired
US6239180 Transdermal therapeutic device and method with capsaicin and capsaicin analogs 06 Nov, 2016 Expired


Given below is the list of recent legal activities going on the following drug patents of Averitas.

Activity Date Patent Number
Patent litigations
Maintenance Fee Reminder Mailed 29 Apr, 2024 US8263059
Payment of Maintenance Fee, 8th Year, Large Entity 28 Jun, 2023 US9226903
Payment of Maintenance Fee, 4th Year, Large Entity 19 Apr, 2023 US10463598
Payment of Maintenance Fee, 8th Year, Large Entity 14 Sep, 2022 US9012469
Payment of Maintenance Fee, 8th Year, Large Entity 04 May, 2022 US8889113
Payment of Maintenance Fee, 8th Year, Large Entity 24 Feb, 2022 US8821920
Payment of Maintenance Fee, 4th Year, Large Entity 25 Jan, 2022 US10034841
Payment of Maintenance Fee, 12th Year, Large Entity 13 Jan, 2022 US7786133
Patent Term Extension Certificate 06 Dec, 2021 US7786133
Payment of Maintenance Fee, 12th Year, Large Entity 15 Jul, 2021 US7662365
Payment of Maintenance Fee, 8th Year, Large Entity 13 May, 2021 US8617530
Mail Certificate of Correction Memo 06 May, 2021 US9012469
Certificate of Correction Memo 05 May, 2021 US9012469
Post Issue Communication - Certificate of Correction 05 May, 2021 US9012469
Notice of Final Determination -Election Required 16 Feb, 2021 US7786133


Averitas's Drug Patent Litigations

Averitas's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Oct 15, 2015, against patent number US7786133. The petitioner Neptune Generics, LLC, challenged the validity of this patent, with NEKTAR THERAPEUTICS as the respondent. Click below to track the latest information on how companies are challenging Averitas's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US7786133 October, 2015 Institution Denied
(27 Apr, 2016)
NEKTAR THERAPEUTICS Neptune Generics, LLC
US7786133 October, 2015 Terminated-Denied
(27 Apr, 2016)
NEKTAR THERAPEUTICS Neptune Generics, LLC


Averitas Drug Patents' Oppositions Filed in EPO

Averitas drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Oct 22, 2014, by Generics (Uk) Ltd (Trading As Mylan). This opposition was filed on patent number EP04814802A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP11829686A Sep, 2016 ABG Patentes, S.L. Patent maintained as amended
EP11829686A Sep, 2016 Stada-Arzneimittel Aktiengesellschaft Patent maintained as amended
EP11829686A Sep, 2016 Generics [UK] Limited Patent maintained as amended
EP04814802A Oct, 2014 Generics (UK) Ltd (trading as Mylan) Opposition rejected


Averitas's Family Patents

Averitas drugs have patent protection in a total of 47 countries. It's US patent count contributes only to 19.4% of its total global patent coverage. 9 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Averitas Drug List

Given below is the complete list of Averitas's drugs and the patents protecting them.


1. Movantik

Movantik is protected by 6 patents, out of which 4 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9012469 Crystalline naloxol-peg conjugate 02 Apr, 2032
(6 years from now)
Active
US7786133 Chemically modified small molecules 16 Sep, 2028
(2 years from now)
Active
US8067431 Chemically modified small molecules 16 Dec, 2024
(10 months ago)
Expired
US7056500 Polymer conjugates of opioid antagonists 29 Jun, 2024
(1 year, 3 months ago)
Expired
US7662365 Polymer conjugates of opioid antagonists 18 Oct, 2022
(3 years ago)
Expired
US8617530 Polymer conjugates of opioid antagonists 18 Oct, 2022
(3 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Movantik's drug page


2. Qutenza

Qutenza is protected by 8 patents, out of which 6 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8821920 Therapeutic patch for transdermal delivery of capsaicin 26 Mar, 2030
(4 years from now)
Active
US9226903 Transdermal therapeutic system comprising an adhesive layer method for siliconizing the back layer or the system and use of said back layer 15 Dec, 2028
(3 years from now)
Active
US10034841 Transdermal therapeutic system comprising an adhesive layer method for siliconizing the back layer of the system and use of said back layer 06 Sep, 2025
(a month ago)
Expired
US10463598 Compositions and kits for the removal of irritating compounds from bodily surfaces 05 Sep, 2023
(2 years ago)
Expired
US10869827 Compositions and kits for the removal of irritating compounds from bodily surfaces 05 Sep, 2023
(2 years ago)
Expired
US8263059 Compositions and kits for the removal of irritating compounds from bodily surfaces 05 Sep, 2023
(2 years ago)
Expired
US8889113 Compositions and kits for the removal of irritating compounds from bodily surfaces 05 Sep, 2023
(2 years ago)
Expired
US6239180 Transdermal therapeutic device and method with capsaicin and capsaicin analogs 06 Nov, 2016
(8 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Qutenza's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List